Business Description
Kinarus Therapeutics Holding AG In Liquidation
ISIN : CH0009115129
Compare
Compare
Traded in other countries / regions
KNRS.SwitzerlandKNRSz.UK IPO Date
2022-06-10Description
Kinarus Therapeutics Holding AG In Liquidation Formerly Kinarus Therapeutics Holding AG is a clinical-stage pharmaceutical company focused on bringing novel treatments to patients suffering from viral, respiratory, and ophthalmic diseases. The company's therapeutic drug candidate, KIN001, consists of a clinical-stage p38 mitogen-activated protein kinase (p38 MAPK) inhibitor, in-licensed from Roche, combined with a marketed drug, together enabling an oral, long-term effective treatment for patients suffering from diseases with serious impact on quality of life.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.05 | |||||
| Equity-to-Asset | 0.51 | |||||
| Debt-to-Equity | 0.48 | |||||
| Debt-to-EBITDA | -0.08 | |||||
| Piotroski F-Score | N/A/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.46 | |||||
| Quick Ratio | 0.46 | |||||
| Cash Ratio | 0.26 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -212.03 | |||||
| ROA % | -130.22 | |||||
| ROIC % | -9.17 | |||||
| ROC (Joel Greenblatt) % | -493668 | |||||
| ROCE % | -157.98 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.68 | |||||
| EV-to-EBIT | -0.18 | |||||
| EV-to-EBITDA | -0.18 | |||||
| EV-to-FCF | -1.43 | |||||
| Earnings Yield (Greenblatt) % | -555.56 | |||||
| FCF Yield % | -115.25 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Kinarus Therapeutics Holding AG In Liquidation Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | 0 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR (€) | 0 | ||
| 20-Day SMA (€) | 0 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (€) | 0 - 0 | ||
| Shares Outstanding (Mil) | 1,299.62 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Kinarus Therapeutics Holding AG In Liquidation Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Kinarus Therapeutics Holding AG In Liquidation Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Kinarus Therapeutics Holding AG In Liquidation Frequently Asked Questions
What is Kinarus Therapeutics Holding AG In Liquidation(FRA:FMZ)'s stock price today?
The current price of FRA:FMZ is €0.00. The 52 week high of FRA:FMZ is €0.00 and 52 week low is €0.00.
When is next earnings date of Kinarus Therapeutics Holding AG In Liquidation(FRA:FMZ)?
The next earnings date of Kinarus Therapeutics Holding AG In Liquidation(FRA:FMZ) is .
Does Kinarus Therapeutics Holding AG In Liquidation(FRA:FMZ) pay dividends? If so, how much?
Kinarus Therapeutics Holding AG In Liquidation(FRA:FMZ) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers